论文部分内容阅读
目的探讨手术结合新辅助化疗治疗局限期小细胞肺癌术前化疗周期对术后临床疗效的影响。方法回顾性分析150例局限期小细胞肺癌(Ⅰ～Ⅱ期)手术患者的临床资料,术前予不同的化疗周期(1个周期、2个周期及3个周期以上),术后化疗6个周期。比较术前不同周期化疗患者5年生存率及术前不同周期化疗对化疗的毒性反应及对术后并发症的影响。结果根治性手术术前化疗2个周期组5年存活率明显较术前化疗1个周期组、3个周期以上组高(P<0.05);术前化疗2个周期组骨髓抑制、肝肾功能异常及术后并发症发生率与术前化疗1个周期组比较差异无统计学意义(P>0.05),但较术前化疗3个周期以上组明显降低(P<0.05)。结论根治性手术结合术前化疗2个周期治疗局限期小细胞肺癌可获得满意的临床效果,且不增加手术危险性。
Objective To investigate the effect of surgery combined with neoadjuvant chemotherapy on the postoperative efficacy of preoperative chemotherapy cycles in patients with locally advanced small cell lung cancer. Methods The clinical data of 150 patients with stage I-II disease were retrospectively analyzed. Six different chemotherapy cycles (one cycle, two cycles and more than three cycles) cycle. To compare the 5-year survival rate of patients undergoing chemotherapy with different cycles before operation and the toxicities of different periods of chemotherapy before chemotherapy to chemotherapy and the postoperative complications. Results The 5-year survival rate of 2 cycles before radical chemotherapy was significantly higher than that of 1 cycle of chemotherapy and 3 cycles of chemotherapy (P <0.05). Preoperative chemotherapy 2 cycles of bone marrow suppression, liver and kidney function The incidence of abnormalities and postoperative complications was not significantly different from that of preoperative chemotherapy in one cycle group (P> 0.05), but significantly lower than that of the preoperative chemotherapy in three cycles (P <0.05). Conclusions Radical surgery combined with preoperative chemotherapy for 2 cycles can achieve satisfactory clinical results in the treatment of small cell lung cancer without increasing the risk of surgery.